Atkins, C, Jassem J. Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide for Metastatic Breast Cancer. J Clin Oncol 2001;19:3441-3442. No abstract available.

Bear HD et al. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165- 74. Abstract

Biganzoli, L et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002;20:3114-21. Abstract

Crown J et al. Docetaxel and Paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004;9(Suppl 2):24-32. Abstract

Desai N et al. Evidence of greater tumor and red cell partitioning and superior antitumor activity of cremophor free nanoparticle paclitaxel (ABI- 007) compared to taxol. Breast Cancer Res Treat 2003; 82(Suppl 1);Abstract 348.

Jassem J et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707- 15. Abstract

Nabholtz J et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001;19:314-21. Abstract

O’Shaughnessy J et al. [44] ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: a phase III trial. Breast Cancer Res Treat 2003;82(Suppl 1);Abstract 44

Valero V, Hortobagyi GN. Are anthracyclinetaxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 2003;21:959-62. No abstract available.

Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004;30(4):333- 42. Abstract

Wist EA et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004;43(1):11-4. Abstract